Nektar Therapeutics (NKTR)

• Market cap: $547M
• 1 day: 6.04%
• 5 days: 8.89%
• 1 month: 21.69%
• 3 months: 184.39%
• 6 months: 145.98%
• Year to date: 99.58%
• 1 year: 41.08%
• 5 years: -90.14%
• 10 years: -80.97%
• Sector: Healthcare
• Industry: Biotechnology

About: Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Employees: 61

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

128% more capital invested

Capital invested by funds: $84.2M [Q1] → $192M (+$108M) [Q2]

8% more call options, than puts

Call options by funds: $20.5M | Put options by funds: $19M

6.41% less ownership

Funds ownership: 66.54% [Q1] → 60.12% (-6.41%) [Q2]

32% less funds holding

Funds holding: 156 [Q1] → 106 (-50) [Q2]

62% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 77

97% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 74

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $85 195% upside
• Avg. target: $103 256% upside
• High target: $120 317% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

B. Riley Securities Mayank Mamtani	195% upside $85	Buy Maintained	8 Jul 2025
HC Wainwright & Co. Arthur He	317% upside $120	Buy Maintained	24 Jun 2025